TWiV 986: Clinical update with Dr. Daniel Griffin

This Week in Virology

Vincent Racaniello

Vincent, Microbe, Medicine, Microbiology, Racaniello, Infection, Virus, Virology, Pathogen, Infectious, Twiv, Science & Medicine

4.8 • 2.2K Ratings

🗓️ 25 February 2023

⏱️ 43 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

In his weekly clinical update Dr. Griffin discusses the efficacy and safety of two RSV vaccines in older adults, health care vaccine mandate remains as some push for an end, past SARS-CoV-2 infection protection against re-infection, a third vaccine dose equalizes the levels of effectiveness and immunogenicity of heterologous or homologous COVID-19 vaccine regimens, Sotrovimab retains activity against SARS-CoV-2 Omicron variant BQ.1.1 in a non-human primate model, effect of higher-dose Ivermectin for 6 Days vs placebo on time to sustained recovery in outpatients with COVID-19, viral burden rebound in hospitalized patients with COVID-19 receiving oral antivirals in Hong Kong, serological response to vaccination in post-acute sequelae of COVID, sex differences in cardiovascular complications and mortality in hospital patients with COVID-19, association of COVID-19 vaccination with risk for incident diabetes after COVID-19, postacute sequelae of SARS-CoV-2 in university setting, the CDC’s long-Covid deception, and podcast companies, once walking on air, feel the strain of gravity. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode RSV prefusion F protein vaccine in older adults (NEJM) Efficacy and safety of an Ad26.RSV.preF–RSV preF protein vaccine (NEJM) Health care vaccine mandate remains as some push for an end (AP) Past SARS-CoV-2 infection protection against re-infection (The Lancet) A third vaccine dose equalizes the levels of effectiveness and immunogenicity of COVID-19 vaccine regimens (medRxiv) Sotrovimab retains activity against SARS-CoV-2 Omicron variant in primate model (bioRxiv) Effect of higher-dose Ivermectin for 6 days vs placebo in patients with COVID-19 (JAMA) Viral burden rebound in patients with COVID-19 receiving oral antivirals (The Lancet) Serological response to vaccination in post-acute sequelae of COVID (BMC) Sex differences in cardiovascular complications and mortality in patients with COVID-19 (BMI) Association of COVID-19 vaccination with risk for incident diabetes after COVID-19 (JAMA) Postacute sequelae of SARS-CoV-2 in university setting (CDC) The CDC’s Long-Covid deception (WSJ) Podcast companies, once walking on air, feel the strain of gravity (NYT) Contribute to our ASTMH fundraiser at PWB Dr. Griffin’s treatment guide (pdf) Letters read on TWiV 986 Don’t crush Paxlovid (pdf) Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]

Transcript

Click on a timestamp to play from that location

0:00.0	This week in virology, the podcast about viruses, the kind that make you sick.
0:10.4	From micro TV, this is twiv this week in virology, episode 986 recorded on February 23rd, 2023.
0:22.1	I'm Vincent Racken-Ello and you're listening to the podcast all about viruses.
0:26.8	Joining me today about 50 miles north of Venezuela, Daniel Griffin.
0:34.8	Hello everyone. What does it mean? It's not in Venezuela, it's in another country.
0:40.4	So it actually isn't another country. I'm in an island about 50 miles north. It's actually a Dutch,
0:46.3	the Dutch Antilles. So yeah, beautiful, beautiful spot.
0:50.7	All right, let's get going before the internet dies.
0:52.7	Yeah, we got a lot to do. So let me start off with my quotation. This is from John Steinbeck
0:58.5	from East of Eden. An unbelieved truth can hurt a man much more than a lie. It takes great courage
1:05.2	to back truth unacceptable to our times. And maybe people will realize later on why I picked that
1:12.4	quotation. But we'll talk a little about RSV first off. A couple exciting articles this week.
1:18.6	And the first one was respiratory, sensational virus, pre-fusion, F protein vaccine, older adults,
1:25.4	published in New and the Journal of Medicine. I hope everyone's excited already just hearing
1:29.1	that title. But these are the results of an ongoing international placebo controlled phase
1:34.0	three trial where they randomly assigned in a one-to-one ratio adult six years of age or older to
1:40.0	receive a single dose of an adjuvated RSV pre-fusion F protein-based candidate vaccine, or placebo,
1:49.2	before the RSV sees. I want you to be thinking about a timing issue here and how that might be
1:55.8	translated into the future. The primary objective was to show vaccine efficacy of one dose
2:03.5	of this vaccine against what RSV-related lower-restraintract disease. Not infection, not PCR positivity,
2:11.8	but RSV-related lower-restraintract disease. And this had to be confirmed by RT PCR.
2:19.1	So here we have vaccine efficacy for PCR confirmed lower-restraintract disease.
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from Vincent Racaniello, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Vincent Racaniello and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.